Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OT: Still can't access either Senecio or DNA Phenomics sites this AM. Hmmmmmm...
Later,
W2P
mingwan0...Maybe it's related to this application:
These SNP markers will comprise a classifier (OVANOME), or predictive genetic test for matching Ovarian Cancer patients with the proper first line chemotherapy dose and/or treatment. We are using these results as a basis for an NIH grant application designed to expand the study and address other aspects of performance that will likely be required before OVANOME could be used to guide chemotherapy decisions in the clinic.
Later,
W2P
mingwan0...Wish I knew of a company that could assist in the standardization of data transfer protocols and data gathering efforts via the internet from virtually "anywhere" in the world. It would also help if such a company were already known to the NIH, having worked for them under previous grants...lol
Later,
W2P
mingwan0...Seems this fits pretty closely with the new NIH initiative. New clinical research methods to streamline the process of bringing findings to the public:
Clinical Research Implementation Group
Harmonization of Clinical Research Regulatory Requirements
This initiative is intended to enhance the leadership and coordination of efforts to harmonize, standardize, and streamline Federal policies and requirements pertaining to clinical research, while emphasizing the integrity and effectiveness of Federal and institutional systems of oversight. As part of its stewardship responsibilities, NIH is responsible for taking steps to foster the responsible conduct of high-quality clinical research.
Integration of clinical research networks.
The efficiency and productivity of the Nation’s clinical research enterprise will be enhanced by promoting clinical research networks capable of rapidly conducting high-quality clinical studies and trials where multiple research questions can be addressed.
Enhance Clinical Research Workforce Training.
The early career development of clinical researchers engaged in all types of clinical research will be supported. These individuals would be expected to achieve excellence in their ability to design and oversee research in multi-disciplinary team research settings, as well as have a high potential to become leaders of various fields of clinical research critical to the overall mission of the NIH and research needs of the nation. In addition, a cadre of NIH National Clinical Research Associates will be established. This group will be composed of community-based practitioners who will receive specialized training in clinical research. These Research Associates will play a critical role both in advancing the discovery process and in disseminating research findings to the community.
Clinical Research Informatics: National Electronic Clinical Trials and Research (NECTAR) Network.
A standardized data system, the National Electronic Clinical Trials and Research (NECTAR) network, will be developed through a phased planning and development process. The network will allow community-based clinicians from the NIH Clinical Research Associates to participate in important national studies, facilitate the sharing of data and resources, and augment clinical research performance and analysis.
Translational Research Core Services.
This effort will facilitate the translation of basic discoveries to early phase clinical testing. It will provide bench and clinical investigators with cost-effective core services, including the expertise needed to move projects through complex logistical and regulatory barriers, and the technical services to synthesize chemical and biological agents for early phase clinical studies.
Regional Translational Research Centers.
These Centers will increase interactions between basic and clinical scientists and accelerate the translational development of new drugs, biomarkers, and treatment strategies from the laboratory bench to clinical testing. New centers will provide essential core infrastructure and support, including specialized cores that provide expertise in biostatistics, clinical pharmacology, pharmacogenetics, and genetics.
Enabling Technologies for Improved Assessment of Clinical Outcomes.
There is a pressing need to better quantify clinically important symptoms and outcomes, including pain, fatigue, and quality of life that are now difficult to measure. Through this effort, new technologies will be developed and tested to measure these self-reported health states and outcomes across a wide range of illnesses and disease severities.
http://nihroadmap.nih.gov/initiatives.asp
Looks like an attempt to take a close look at how clinical information is gathered and to streamline and shorten the clinical trial process.
Later,
W2P
vision...Yes it does, thanks. BTW, they can work on the updates offline, but would have to interrupt the site temporarily to update the code...I believe...lol
Later,
W2P
IVRT...Thanks for confirming my temporary sanity...lol
Later,
W2P
mahastock...Thanks. When I saw that other information you posted over on RB the bulb finally went on. It makes sense now.
Later,
W2P
mjam...May have spoken too soon! lol Although, the suggestion that they have abandoned the products is ludicrous, this may or may not explain the abandonment of the TM's.
I would swear it used to say TM though, and not SM. Anybody else remember Retinome(SM)?
Later,
W2P
Re: Servicemarks...might be back to square one. If SM's are substantially the same as TM's, they should still be registered with USPTO. And speaking of website "updates", USPTO has a new face tonight.
Later,
W2P
itsonlymuni...I believe my own eyes, and what I saw from retro and from the "Strategic Alliance" search on the Senecio website that night leads me to believe there is or will be some sort of relationship. Not to mention the fact that the description of the Methods of Discovery from the DNA Phenomics website looks as if it could have been written by Tony.
You can't see the evidence now, because it was VERY quickly removed after we started posting about it and asking questions of the company. But if you go back in the archive here, you'll see what it was all about.
Later,
W2P
Here's a definition of "Servicemark":
Service Mark
A service mark is any word, name, symbol, device, or any combination, used, or intended to be used, in commerce, to identify and distinguish the services of one provider from services provided by others, and to indicate the source of the services. A service mark is processed and treated substantially the same a TRADEMARK.
But here's how it differs from a Trademark:
Trademark
A trademark is a word, name, symbol or device which is used in trade with goods to indicate the source of the goods and to distinguish them from the goods of others. A servicemark is the same as a trademark except that it identifies and distinguishes the source of a service rather than a product. The terms "trademark" and "mark" are commonly used to refer to both trademarks and servicemarks.
Trademark rights may be used to prevent others from using a confusingly similar mark, but not to prevent others from making the same goods or from selling the same goods or services under a clearly different mark. Trademarks which are used in interstate or foreign commerce may be registered with the Patent and Trademark Office. The registration procedure for trademarks and general information concerning trademarks is described in a separate pamphlet entitled "Basic Facts about Trademarks".
Later,
W2P
OK, it means "Servicemark"...get your google on! lol
Later,
W2P
maha...lol Don't know...gotta check it out. In fact, at first I wasn't sure it didn't ALWAYS say SM. I think it was TM though.
Later,
W2P
Website Updates:
Check this out. All that frantic discussion yesterday on RB about the "abandonment" of Retinome because they let the TM lapse. Check out the website...it's now Retinome(SM).
http://www.dnaprint.com/retinome.html
Later,
w2P
jcryan19...I don't know. I know that the PP Executive Summary says that the first conversion rate was set at $0.061. Based on that and how the calculation works, I pegged the start for some time in mid-to-late July. It's possible it didn't start until later though. All you have to do is look at days when the preceding 20-day moving average was $0.072 and you can get a pretty good idea when it started.
The agreement itself is confidential, so I don't know whether there are any clauses that would readjust the initial conversion prior to the close.
I also know, from reading Luchese's agreement in the May 10Q that he has a clause that adjusts his holdings in the placement to meet the best terms given to any other private placement participants.
I think it's just a case where some are out of the stock and it is in their best interest to drive it as low as possible. Certainly, anyone visiting RB these days, that didn't know the company, would be frightened away. That's their motive IMO.
Secondarily, I wonder some times if they're not just goading us into telling them when their next re-entry time is. I don't think it's a price, per se, td looks for events. In the meantime, he just does his thing and waits for us to do our DD and throw it back in his face.
Later,
W2P
vision2b...Fantastic article. Thanks for posting.
Later,
W2P
ice...DNA Phenomics is part of the Multimedia Center over there. They intend to take part in the Malaysian grant program. When they file their application, all parties are required to sign "confidentiality" agreements.
Put it this way, I would be concerned if fatboy22 had gotten a negative answer. BTW, that would be a simple response to make if there were no relationship whatsoever.
But I don't consider a "no-response" as alarming.
Later,
W2P
Slopster...You can find him if you search the net. New College is New College Florida. The guy interned at DNAP (summer of 2002 I believe). Looks like now he works there full time.
Later,
W2P
big...I tend to believe that post as well for the same reasons you sighted. This whole episode appears to revolve around a friend or relative of a disgruntled former employee creating some havoc.
Kondragunta DID file a 144 back on June 20th by the way. Here's the link:
KUNDRAGUMTA VENKATES SH 6/20/2003 887,686 PRUDENTIAL SECUR...
http://www.nasdaq.com/asp/holdings.asp?mode=&kind=&symbol=AIPN&symbol=DNAP&symbol=&a...
As far as all the other allegations being tossed around, I see it as yet another in a series of attempts by a few slander the company for their own pruposes. Lie, cheat, and steal...it matters not to some.
BTW, did you happen to notice that the 8-K filed yesterday appeared to be quite an upgrade in professional appearance from anything the company has filed in the past? Check it out.
Have a great day,
W2P
Very Interesting Post from RB. ALL Should Read:
http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&read=274204
Later,
W2P
elllk...Tony is listed as the CEO on the website, is he not? When was that change made? Where is Gabriel, Gomez, Tamborini?
They are in the process of reworking the website. IR has told people several times over the last several weeks that an update is imminent. I suppose we shall see more then.
And no, his resignation was NOT recent. As I have posted, now FOUR times, he is not listed among management in the company's year end report. That was filed in early April 2003. It seems obvious to me, and has since the 2003 10K was filed, that Kondragunta was no longer an officer of the company.
Later,
W2P
commando...What's to understand. The company is being restructured. Tony told us in the TWST article that they are working hard "right NOW" to acquire their own drug pipeline. Kondragunta submitted a letter of resignation, he wasn't fired. It's business.
You know, Kondragunta said they don't have any money. Last I checked the most recent 10Q showed $400K in the bank. Last I checked, Athena Capital partners was executing a PP. BTW, they have garnered at least $2Million from that placement to date.
Maybe you ought to make a few more phone calls before you go off the deep end. Of course, that's JMHO, and you're welcome to panic if you so choose.
Later,
W2P
2ys2retire...That would be Gabriel's private residence. He has a house in Massachusetts.
Later,
W2P
Ah, Slopster...a voice of reason. Let me add a couple of more things. Why would they be going through a private placement? If they acquire or merge with a pharma company, won't they have scientists? Will they have management people (with Business Management backgrounds) of their own that will have to be integrated into the operation? Afterall, that IS the stated plan, is it not?
Re-read the TWST article folks. Ask the folks that attended the Texas conference what got them all so wound up.
Later,
W2P
I have told people in several past posts that Kondragunta wasn't listed among the officers in the year end report filed last April...LAST APRIL...There are two others, however, that got promotions. I have posted about that too. Perhaps Dr. Kondragunta was not executive material or didn't fit into the new company structure.
The company is transitioning from Development Stage to Commercial Stage. Does it really surprise you that there would be some personnel moves in the course of that process? Does it really surprise you that some who may have held prominent positions in the past, may have to either adjust to a new reality or leave? Does it really surprise you that those affected might not be too happy about it? Bottom line, that's business boys and girls.
Here it is again for those that missed it the first several times it was posted:
DNAPrint genomics is a consumer oriented genomics company, focused on developing products that enable consumers to utilize the information inherent in their genomes (DNA sequence). Our management team consists of Hector Gomez, MD, Chairman of the Board, Richard Gabriel, CEO/President, Tony Frudakis, Ph.D., CSO, K. Suresh Chandra, Ph.D., Director of Statistical Genomics, and K. Punniswamy, Ph.D., President of Statistical Genomics. The Company believes that these executives have the necessary expertise to make us a leader in the development of genetic tests and products for the consumer genomics marketplace.
This is NOT news to some of us that are paying attention and doing our homework.
Later,
W2P
Teamlasvegas...Great link. Thanks. eom
Later,
W2P
Grateful...Saw your note here, and wanted to offer this. DNA Phenomics is part of the Multimedia Super Corridor. That's where they would be applying for the Malaysia grant money that is being made available to the Corridor companies.
I looked through the site, and found that as part of the grant application, ALL parties must sign non-disclosure agreements as part of the grant submittal.
Follow this link and look at the bottom of the graphic:
http://www.msc.com.my/cs/mgs/approval.asp
Not saying that is definitely what is going on here, but it would offer a possible explanation for what we were told.
Later,
W2P
Older story, but VERY interesting:
http://www.yourlawyer.com/practice/news.htm?story_id=2884&topic=Baycol
Cholesterol Medicine’s Side Effects Questioned
Statins Cited In Nerve And Muscle Studies
Newsday - Debbe Geiger
10/29/02 - Since their introduction nearly 20 years ago, statins have become one of the most popular classes of drugs in the world. Millions of people take them to lower their cholesterol, because the drugs prevent death and heart attacks, decrease arterial plaque and reduce the incidence of stroke. Dr. Paul Phillips, a cardiologist in San Diego, says that "statins are great medicine. They are truly safer than aspirin."
Though their safety and effectiveness have been proven in long-term clinical trials on more than 50,000 people, statins have come under fire recently for causing adverse side effects, including muscle pain and nerve damage. One study, published last month in the Annals of Internal Medicine, found that in some people the muscle damage may be going undetected. Left untreated, that can lead to a rare but more serious muscle disorder called rhabdomyolysis, which can cause kidney failure and death.
More than a year ago, Baycol (cerivastatin) was voluntarily withdrawn from the market after it was linked to 31 deaths caused by rhabdomyolysis. It's not clear just why Baycol was linked to so many deaths compared to the other statins - Mevacor (lovastatin), Pravachol (pravastatin sodium), Zocor (simvastatin), Lescol (fluvastatin sodium) and Lipitor (atorvastatin calcium).
About half the cases were found in patients who also were taking Lopid (gemfibrozil), another cholesterol-lowering agent. According to Dr. Antonio Gotto, a professor of medicine and dean of the Weill Cornell Medical College in New York, "The Lopid interfered with the breakdown of Baycol, so there was a much higher level of exposure of the drug to the muscle." However, the other half involved use of Baycol alone. "It just turned out that Baycol had more toxicity to muscle than the other statins," Gotto said.
The other statins have been shown to cause muscle pain and tenderness, and Phillips is concerned that more serious muscle damage may be going unchecked because many doctors don't change their patients' statin therapy unless they find elevated levels of a muscle enzyme called creatine kinase. As the lead author of the Annals of Internal Medicine study, Phillips reported that muscle disorders may be present when creatine kinase levels are normal. In research Phillips conducted at Scripps Mercy Hospital in San Diego, where he is director of interventional cardiology, he found evidence of four people with muscle symptoms associated with statin therapy who did not have any changes in their creatine kinase levels.
"We decided to report on the four people before we finished the trial because the results were really significant," said Phillips. "Even though it was a small number, they represent a much larger group, and they are the first proof that creatine kinase is not a sensitive enough indicator."
That's important, he says, because a June advisory from the Joint American College of Cardiology, American Heart Association, and the National Heart Lung and Blood Institute told doctors to keep patients on statins if their creatine kinase remains less than 10 times normal even if they have muscle complaints. "The advisory came out because some people are unnecessarily stopping their statins," Phillips said. "It was important that they put out this advisory, but it highlights how little we know about their toxicity."
A recent study published in the journal Neurology also links statins to nerve damage in the form of weakness, tingling and pain in the hands and feet, as well as difficulty walking. According to the report, which looked at 500,000 Danish residents, one year of statin therapy raised the risk of nerve damage by about 15 percent. Taking statins for two years raised the risk to 26 percent.
Phillips says the Danish study provides "just one more example of a toxicity that wasn't picked up [in earlier] trials, largely because they aren't designed to look at toxicity. They are designed to look at efficacy."
He believes the new studies suggest the need for changing the current guidelines. "Because they [statins] are so safe, our current guidelines have accelerated who we should give them to. People with lower cholesterol are recommended to be on the drug because they have no toxicity. Maybe we shouldn't be using the drugs on everyone."
Gotto, a leading investigator in one of the statin trials and a consultant to several pharmaceutical companies that manufacture the drugs, disagrees. Now, about 12 million Americans are taking statins. But "up to 36 million Americans should be on statin therapy," according to the guidelines, he says.
"I think we're underusing them," he said. "People with a wide variety of diseases are treated with statins. I'm not saying we should ignore the observations, but to reduce the recommendations for the use of statins based on this would be irresponsible."
Doctors are also concerned that the recent reports will prompt patients to stop taking their medicine. "It's important to note that these results are preliminary," says Dr. Allison Spatz, director of the coronary care unit at North Shore University Hospital in Manhasset. "The numbers of patients who experience muscle symptoms without elevation of [creatine kinase] were really small. More studies need to be done. It's not a reason to stop your statins."
Bernard Siegal, 69, a pharmacist from Roslyn, began experiencing sharp back pain five years after he started taking Mevacor, but he was switched to Zocor and hasn't complained since. He knows the benefits of statin therapy far outweigh the risks.
"There is always a controversy," he says. "It's all a risk, whatever you do in life. I figure, I survived this long, I'll go with the program."
Anyone experiencing muscle tenderness and soreness from statin therapy should speak with his or her doctor. It's possible the condition can be remedied. For example, Louise Spadaro, a cardiologist in Roslyn, switches her patients to different medications - people react differently to each statin - or she suggests taking the medicine at different times of the day, with food or with lots of water. Spadaro has also been able to reduce muscle symptoms by combining therapy with antioxidants. However, that must be done under a physician's care because some vitamins, such as niacin, can exacerbate muscle aches.
Later,
W2P
OT: Miss Scarlet...Don't be too hasty. What do we know...I am not retired, neither is the Pope...I have Polish ancestry, so does the Pope...I am in church every Sunday, so is the Pope...I tend to be a little "preachy", so does the Pope...hhhmmm lol
BTW, when "He maketh you to lie down in green pastures" it sounds as if you will be properly attired.
Peace be with you,
W2P
Broke...I have already offered my opinions. You can check my archive if you'd like to know where I stand.
Later,
W2P
OT: Miss Scarlet...were you afraid I was working for the "other" side? LOL So you see, if we don't meet at a DNAPrint shareholders meeting some day, we shall surely meet in Heaven!
BTW, in answer to one of your old questions, no, I am not retired either.
Peace be with you,
W2P
firefight4...Contact Athena Capital for a copy of the Executive Summary and further details on the placement. It is available to "Accredited Investors" as defined by the SEC. There are income and net worth limitations in order to participate. It has nothing to do with how many, if any, shares you currently own. IMO it's good for the company and good for the existing shareholders.
Good Luck,
W2P
early...Oh, you were wondering if I am a recovering alcoholic. No I am not...an alcoholic that is, nor am I recovering. lol I rarely drink.
I am a Christian, however, and am well acquainted with the serenity prayer...and a few others. The prayer of Jabez is a wonderful prayer. Are you familiar with that one?
Later,
W2P
itsonlymuni...Not only "honorable", perfectly legitimate. What was posted were details out of the Executive Summary for the confidential private placement agreement. The agreement itself should be held in confidence, the Executive Summary is designed for distribution or Athena wouldn't be mailing it out unless they had first prequalified the inquiring investor.
Later,
W2P
early...The "God grant me..." wasn't for me, it was for ustacud! lol He seemed to be having a tough day and I was only trying to offer some words of encouragement and advice on keeping things in perspective.
Appreciate the concern though.
Have a Great Day,
W2P
chris...I already HAVE the senility covered...lol eom
Dick...It has happened to all of us...best thing to do is take ice's advice. The more you watch the more frustrating it becomes.
It also helps to look back at the steps that have been taken in the last year, and the order they have been taken. You'll see that they ain't getting ready to go broke!
I do feel bad for some of the died in the wool longs that ran out of patience. I think they'll regret not hanging a while longer, but that's JMO. Everyone invests according to their own risk tolerance and personal constitution. It just so happens I have an incredibly "thick" skull, and have always leaned towards operating out on the edge! lol
Do what you're comfortable with, and above all else, don't let it affect the other aspects in your life. You have no control over what's going to happen here, but you are the only one with control of your life.
"God grant me the serenity..."
Good Luck,
W2P
Has anyone noticed that they seem to be going back and forth with the layout of the AncestryByDna website design?
It had been changed and updated, but the current Home Page is back to the "old" one. Depending on which day you check, the layout changes back and forth.
http://www.ancestrybydna.com
Curious...
Later,
W2P
OT: mjam...Arch plays the game better than you might imagine...sometimes you just let'm believe what they want to believe. lol
Later,
W2P
stak...You are a truly unique individual. Thanks, I enjoyed it immensely!
Later,
W2P